Tranylcypromine (Tracydal®) in patients with a severe multi-resistant depressive disorder

Zorginstituut Nederland carried out a budget impact analysis for the medicine tranylcypromine (Tracydal®). They reached the following conclusion.
Based on the currently applicable criteria of the Medicines Reimbursement System (GVS), tranylcypromine is not mutually replaceable with any product in the GVS. For this reason the Zorginstituut advises that tranylcypromine (Tracydal®), 20-mg (film-coated) tablet, is placed on List 1B of the GVS.